To include your compound in the COVID-19 Resource Center, submit it here.

Hatching Pandion

Why Polaris built its own platform for immunology play Pandion

After scouring academia for novel treatment approaches to autoimmune and inflammatory diseases and coming up empty-handed, Polaris Partners formed Pandion Therapeutics Inc. to develop its own platform from the ground up.

Backed with a $58 million series A round, Pandion

Read the full 397 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers